Save time and jump to the most important pieces.
424B3 - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
8-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
8-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)
SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)
SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)
Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.76) by 46.05 percent. This is a 72.79 percent increase over losses of $(4.08) per share from the same period last year.
Quoin Initiates Peeling Skin Syndrome Clinical Program Further Expansion of International Reach for Netherton Syndrome Clinical Trials Significant Insider Share Purchases by the Entire Management Team ASHBURN, Va., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical-stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the three and nine months ended Sept. 30, 2024. Quoin CEO Dr. Michael Myers said, "The third quarter has been marked by notable achievements, including expanding the c
Clinical Assessment Is Being Performed on a Pediatric Patient at Children's Health Ireland in Dublin First Evaluation of QRX003 in a Pediatric Patient Second Clinical Site to Open in Spain with Potentially Three Additional Pediatric Netherton Patients ASHBURN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX), a clinical-stage specialty pharmaceutical company focused on novel treatments for rare and orphan diseases, today announced that it has initiated the testing of the safety and efficacy of QRX003 in a young child with Netherton Syndrome (NS), a rare inherited genetic disease. There is currently no approved treatment for NS and no cure. The cli
ASHBURN, Va., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its third quarter 2024 financial results before the market opens on Thursday, November 7, 2024. The announcement will provide an operational update regarding the Company's achievements during the quarter and will detail financial highlights. About Quoin Pharmaceuticals Ltd.Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare a
Quoin Initiates Peeling Skin Syndrome Clinical Program Further Expansion of International Reach for Netherton Syndrome Clinical Trials Significant Insider Share Purchases by the Entire Management Team ASHBURN, Va., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical-stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the three and nine months ended Sept. 30, 2024. Quoin CEO Dr. Michael Myers said, "The third quarter has been marked by notable achievements, including expanding the c
Quoin Broadens Product Portfolio through Research Agreement with University College Cork, Ireland Company Expands On-going Clinical Trials in Netherton Syndrome to Include International Sites Announced Plans to Initiate Clinical Study in Peeling Skin Syndrome Continues to Evaluate M&A Opportunities in Rare and Orphan Diseases ASHBURN, Va., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the three and six months ended June 30,
ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its fourth quarter and 2023 financial results after the market closes on Wednesday, March 13, 2024. The Company will host a conference call and webcast at 8:30am ET on Thursday, March 14, 2024. The call will include a discussion of fourth quarter and 2023 financial results and a corporate update. The live call can be accessed by dialing 1-800-603-0527 (domestic) or 1-412-317-0688 (international). The live and archived webcast of the
4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)
4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)
4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)
4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)
4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)
4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)